Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:histone_deacetylase_inhibitor |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX45
|
| gptkbp:brand |
gptkb:Beleodaq
|
| gptkbp:CASNumber |
414864-00-9
|
| gptkbp:developer |
gptkb:Spectrum_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
1.1 hours
|
| gptkbp:hasMolecularFormula |
C15H14N2O4S
|
| gptkbp:hasSMILES |
CC(=O)Nc1ccc(cc1)S(=O)(=O)N=Cc2ccco2
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits histone deacetylases
|
| gptkbp:metabolism |
liver
|
| gptkbp:PubChem_CID |
CHEMBL1201836
5293776 6918637 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
fever nausea vomiting fatigue infections dyspnea |
| gptkbp:synonym |
PXD101
|
| gptkbp:UNII |
KXJ3Q6N1GA
|
| gptkbp:usedFor |
treatment of peripheral T-cell lymphoma
|
| gptkbp:bfsParent |
gptkb:Histone_deacetylase
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
belinostat
|